Does Rallies show Form 4 insider transactions for IART?

Yes. Rallies tracks IART insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IART research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IART. It does not provide personalized investment advice.

IART (Integra LifeSciences Holdings) Stock Analysis - Insider Trades

Integra LifeSciences Holdings (IART) is a publicly traded Healthcare sector company. As of May 21, 2026, IART trades at $15.40 with a market cap of $1.10B and a P/E ratio of -2.33. IART moved +7.06% today. Year to date, IART is +22.53%; over the trailing twelve months it is +15.54%. Its 52-week range spans $8.70 to $27.13. Analyst consensus is neutral with an average price target of $15.60. Rallies surfaces IART's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IART stock inside the company?

Recent IART insider activity includes GRAVES JEFFREY A bought 9.00K, Schwartz Eric sold 4.07K, McBreen Michael J. sold 1.70K, and Mosebrook Jeffrey sold 1.19K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IART Key Metrics

Key financial metrics for IART
Metric	Value
Price	$15.40
Market Cap	$1.10B
P/E Ratio	-2.33
EPS	$-6.46
Dividend Yield	0.00%
52-Week High	$27.13
52-Week Low	$8.70
Volume	112
Avg Volume	0
Revenue (TTM)	$1.64B
Net Income	$-495.80M
Gross Margin	51.94%

Recent IART Insider Trades

GRAVES JEFFREY A bought 9.00K (~$102.15K) on Nov 5, 2025.
Schwartz Eric sold 4.07K (~$100.10K) on Dec 3, 2024.
McBreen Michael J. sold 1.70K (~$41.06K) on Dec 2, 2024.
Mosebrook Jeffrey sold 1.19K (~$25.70K) on Aug 19, 2024.

Latest IART News

Integra sees 2.4% Q1 revenue growth to $391.9M and names new CEO — May 5, 2026
Integra to Present 985-Case PriMatrix Dermal Scaffold Data at April Meetings — Apr 7, 2026
Integra LifeSciences Guides Q1 Revenue 2.8% Below Estimates, Margins Plunge — Feb 26, 2026
Integra LifeSciences Q4 Revenues Dip 1.7%, Adjusted EPS Falls to $0.83 — Feb 26, 2026
Integra LifeSciences Sees Revenue Guidance Miss, Forecasting 2.7% Sales Drop — Feb 25, 2026

IART Analyst Consensus

8 analysts cover IART: 0 strong buy, 1 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $15.60.

Common questions about IART

Who is trading IART stock inside the company?: Recent IART insider activity includes GRAVES JEFFREY A bought 9.00K, Schwartz Eric sold 4.07K, McBreen Michael J. sold 1.70K, and Mosebrook Jeffrey sold 1.19K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IART?: Yes. Rallies tracks IART insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IART research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IART. It does not provide personalized investment advice.